ReviewClinical lymphoma & myeloma2009
Minimal residual disease quantitation in acute myeloid leukemia.
Review in Clinical lymphoma & myeloma, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 46 citations in OpenAlex.
- Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.Ochsner journal · 2017Review
- Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2015Article
- Nanotechnology applications in hematological malignancies (Review).Oncology reports · 2015Review
- Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2014Article
- Advances and issues in flow cytometric detection of immunophenotypic changes and genomic rearrangements in acute pediatric leukemia.Translational pediatrics · 2014Review
- Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient.Molecular cytogenetics · 2014Article
- Superior mediastinal syndrome : a rare presenting feature of acute myeloid leukemia.Indian journal of pediatrics · 2013Article
- Measurements of treatment response in childhood acute leukemia.The Korean journal of hematology · 2012Article
- Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Article
- Minimal residual disease.Leukemia supplements · 2012Article
- How I treat pediatric acute myeloid leukemia.Blood · 2012Review
- Article
- Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Article
- Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The prognosis for patients with acute myeloid leukemia (AML) is heterogeneous. A minority of patients have clinical and biologic features associated with a very high risk of relapse. For the remaining patients, no clear prognostic factors can be identified at diagnosis. The degree of treatment response is likely to be an informative predictor of outcome for these patients. Modern assays to detect AML cells that are undetectable by conventional morphologic techniques, ie, minimal residual disease (MRD), can potentially improve measurements of treatment response. It is plausible that modifications to treatment based on the results of these assays will improve clinical management and ultimately increase cure rates. Established MRD assays for AML are based on either polymerase chain reaction amplification of genetic abnormalities or flow cytometric detection of abnormal immunophenotypes. Residual disease and treatment response can be measured by these assays in a manner that is much more sensitive and objective than that afforded by conventional morphologic examination. The expanding use of MRD testing is beginning to change the definitions of treatment response and of remission. Other clinically informative uses of MRD testing include the detection of early relapse and the evaluation of the efficacy of new antileukemic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.